Oakville, Ontario — November 18, 2025 — Leads & Copy — FORUS Therapeutics announced that XPOVIO® (selinexor) is now publicly funded in Quebec for treating multiple myeloma, effective November 6, 2025.
Kevin Leshuk, president and CEO of FORUS, said the INESSS process was successfully completed. This is an important step to give patients in Quebec equal access to XPOVIO.
Myeloma Canada also praised Quebec’s decision to fund XPOVIO for multiple myeloma patients. Martine Elias, M. Sc., CEO of Myeloma Canada, said XPOVIO offers new hope and expands the treatment options for patients. It is an innovative treatment with a novel mechanism of action for patients with early relapsed or refractory disease.
FORUS Therapeutics Inc. is a Canadian biopharmaceutical company dedicated to developing new medicines for hematological cancers and other forms of cancer. The company’s mission is to accelerate unique and important treatments that improve lives for cancer patients, caregivers, physicians and partners.
For media inquiries, contact Kevin Leshuk at media@forustherapeutics.com.
Source: FORUS Therapeutics
